Durham said that he voted no because of poor characterization of the compound and the potential risk with carcinogenicity. William Zamboni, a pharmacologist at the University of North Carolina said that he voted no because he felt there was a significant lack of data on the safety of the product.
Whether this carries clinical significance requires longer-term cardiovascular outcome data that is not yet available
Take control of your health today, call to get started
There seems to be a lot of conversation circulating lately, regarding GLP-1 medications like Semaglutide and Tirzepatide as to if these medications are a long-term, sustainable weight loss solution
In the FY 2021 IPPS final rule we stated that taken as a whole, we continued to believe that the body of research discussed in that rulemaking suggests that payer specific charges negotiated between hospitals and MA organizations are generally well-correlated with Medicare IPPS payment rates, and payer-specific charges negotiated between hospitals and other commercial payers are generally not as well-correlated with Medicare IPPS payment rates
In any weight loss planwhether through medication, dieting, or surgery some lean body mass loss is expected
